Testing a Dendritic Cell Vaccine With Pembrolizumab for Breast Cancer That Has Spread to the Brain

Official title: Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.

The trial team last updated this record on .

The short version

This study is testing whether two immune treatments, given together, can help people whose breast cancer has spread to the brain.

Read our full plain-language summary

What the trial team says

This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the cancer cells. . Pembrolizumab is an "immune checkpoint inhibitor" which is designed to either "unleash" or "enhance" the cancer immune responses that already exist by either blocking inhibitory molecules" or by activating stimulatory molecules. Giving dendritic cell vaccines and pembrolizumab may shrink the cancer.

From the trial's own listing on ClinicalTrials.gov.

Key facts

Registry number
NCT04348747
Stage of testing
Phase 2
Conditions studied
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8

Where it is running

This trial lists 3 sites.

How to use this

Talk to your care team first. They know your history and can tell you whether this trial is worth your time.

Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.

See the full listing on ClinicalTrials.gov

This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.